Vancomycin-resistant Staphylococcus aureus

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Vancomycin-resistant Staphylococcus aureus
Synonyms	VRSA
Pronounce	N/A
Specialty	N/A
Symptoms	Skin infection, pneumonia, sepsis
Complications	Endocarditis, osteomyelitis, toxic shock syndrome
Onset	Varies
Duration	Varies
Types	N/A
Causes	Staphylococcus aureus with antibiotic resistance to vancomycin
Risks	Previous antibiotic use, hospitalization, immunocompromised state
Diagnosis	Culture, antibiotic susceptibility testing
Differential diagnosis	Methicillin-resistant Staphylococcus aureus (MRSA), other bacterial infections
Prevention	Infection control, hand hygiene, judicious use of antibiotics
Treatment	Alternative antibiotics such as linezolid, daptomycin
Medication	N/A
Prognosis	Varies, can be severe if untreated
Frequency	Rare
Deaths	N/A

3D structure of Rifampicin, an antibiotic used against S. aureus

S. aureus colonies on blood agar

Vancomycin-resistant Staphylococcus aureus (VRSA) is a strain of the bacterium Staphylococcus aureus that has developed resistance to the antibiotic vancomycin. This resistance poses significant challenges in the treatment of infections caused by this bacterium.

History

The first case of VRSA was reported in 2002 in the United States. The emergence of VRSA is a result of the bacterium acquiring the vanA gene from vancomycin-resistant enterococci (VRE), which confers high-level resistance to vancomycin.

Mechanism of resistance

VRSA acquires resistance through the horizontal transfer of the vanA gene cluster, which alters the target site of vancomycin, reducing its binding affinity. This genetic exchange typically occurs in environments where both VRE and S. aureus are present, such as in hospitals.

Clinical significance

Infections caused by VRSA are difficult to treat due to limited antibiotic options. VRSA infections can lead to severe outcomes, especially in immunocompromised patients. The resistance to vancomycin necessitates the use of alternative antibiotics, such as linezolid or daptomycin, which may have their own limitations and side effects.

Prevention and control

Preventing the spread of VRSA involves strict infection control measures in healthcare settings, including hand hygiene, contact precautions, and surveillance cultures. Reducing the use of vancomycin and other antibiotics can also help prevent the development of resistance.

Research and future directions

Ongoing research aims to develop new antibiotics and alternative therapies to combat VRSA. Efforts are also focused on understanding the genetic mechanisms of resistance and the epidemiology of VRSA to better control its spread.

See also

• Methicillin-resistant Staphylococcus aureus
• Antibiotic resistance
• Vancomycin